<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>ACYCLOVIR- acyclovir ointment </strong><br>Mylan Pharmaceuticals Inc.<br></p></div>
<h1></h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_4bf19e1b-2dcc-4bed-8a12-f2d7d6a4e1d0"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Acyclovir Ointment, USP is a synthetic nucleoside analogue active against herpes viruses. Acyclovir Ointment 5% is a formulation for topical administration. Each gram of Acyclovir Ointment 5% contains 50 mg of acyclovir in a polyethylene glycol (PEG) base.</p>
<p>Acyclovir, USP is a white to off-white, crystalline powder with the molecular formula C<span class="Sub">8</span>H<span class="Sub">11</span>N<span class="Sub">5</span>O<span class="Sub">3</span> and a molecular weight of 225. The maximum solubility in water at 37°C is 2.5 mg/mL. The pka’s of acyclovir are 2.27 and 9.25. The chemical name of acyclovir is 9-[(2-Hydroxyethoxy)methyl]guanine; it has the following structural formula:</p>
<div class="Figure">
<a name="id236"></a><img alt="Acyclovir Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce3d5e8b-9401-40be-8ce7-4ea42113f4ab&amp;name=ab3c9c7e-1bda-4579-9b90-2133c99c95a8-01.jpg">
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_d0090145-e91e-48f2-bbbe-3f34150b8c18"></a><a name="section-2"></a><p></p>
<h1>VIROLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_a0cd89e2-4b65-4bf6-8aa3-159fec740c42"></a><a name="section-2.1"></a><p></p>
<h2>Mechanism of Antiviral Action</h2>
<p class="First">Acyclovir is a synthetic purine nucleoside analogue with <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2) and <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster virus (VZV).</p>
<p>The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. <span class="Italics">In vitro</span>, acyclovir triphosphate stops replication of herpes viral DNA. This is accomplished in three ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the viral TK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_e55d16ac-2b0e-495b-80fa-c69792a99a65"></a><a name="section-2.2"></a><p></p>
<h2>Antiviral Activities</h2>
<p class="First">The quantitative relationship between the <span class="Italics">in vitro</span> susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans and virus sensitivity testing has not been standardized. Sensitivity testing results, expressed as the concentration of drug required to inhibit by 50% the growth of virus in cell culture (IC<span class="Sub">50</span>), vary greatly depending upon a number of factors. Using plaque-reduction assays, the IC<span class="Sub">50</span> against herpes simplex virus isolates ranges from 0.02 to 13.5 mcg/mL for HSV-1 and from 0.01 to 9.9 mcg/mL for HSV-2. The IC<span class="Sub">50</span> for acyclovir against most laboratory <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> and clinical isolates of VZV ranges from 0.12 to 10.8 mcg/mL. Acyclovir also demonstrates activity against the Oka vaccine <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> of VZV with a mean IC<span class="Sub">50</span> of 1.35 mcg/mL.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_95fadf95-6757-4781-83a0-e2adc57c9f90"></a><a name="section-2.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4150981" conceptname="Drug resistance">Drug Resistance</span></h2>
<p class="First">Resistance of HSV and VZV to acyclovir can result from qualitative and quantitative changes in the viral TK and/or DNA polymerase. Clinical isolates of HSV and VZV with reduced susceptibility to acyclovir have been recovered from immunocompromised patients, especially with advanced <span class="product-label-link" type="condition" conceptid="439727" conceptname="Human immunodeficiency virus infection">HIV infection</span>. While most of the acyclovir-resistant mutants isolated thus far from immunocompromised patients have been found to be TK-deficient mutants, other mutants involving the viral TK gene (TK partial and TK altered) and DNA polymerase have been isolated. TK-negative mutants may cause severe disease in infants and immunocompromised adults. The possibility of viral resistance to acyclovir should be considered in patients who show poor clinical response during therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_9f24053a-dadb-4cf8-84e4-4dfec53bf289"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Two clinical pharmacology studies were performed with acyclovir ointment 5% in immunocompromised adults at risk of developing mucocutaneous herpes simplex virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or with localized <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. These studies were designed to evaluate the dermal tolerance, systemic toxicity and percutaneous absorption of acyclovir.</p>
<p>In one of these studies, which included 16 inpatients, the complete ointment or its vehicle were randomly administered in a dose of 1 cm strips (25 mg acyclovir) 4 times a day for 7 days to an intact skin surface area of 4.5 square inches. No local intolerance, systemic toxicity or <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span> were observed. In addition, no drug was detected in blood and urine by radioimmunoassay (sensitivity, 0.01 mcg/mL).</p>
<p>The other study included 11 patients with localized <span class="product-label-link" type="condition" conceptid="434272" conceptname="Varicella">varicella</span>-zoster <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. In this uncontrolled study, acyclovir was detected in the blood of nine patients and in the urine of all patients tested. Acyclovir levels in plasma ranged from &lt; 0.01 to 0.28 mcg/mL in eight patients with normal renal function, and from &lt; 0.01 to 0.78 mcg/mL in one patient with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Acyclovir excreted in the urine ranged from &lt; 0.02% to 9.4% of the daily dose. Therefore, systemic absorption of acyclovir after topical application is minimal.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_5342a0e5-14c3-4a24-b320-c1b55f7bb940"></a><a name="section-4"></a><p></p>
<h1>CLINICAL TRIALS</h1>
<p class="First">In clinical trials of initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> infections, acyclovir ointment 5% has shown a decrease in healing time and, in some cases, a decrease in duration of viral shedding and duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. In studies in immunocompromised patients mainly with <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span>, there was a decrease in duration of viral shedding and a slight decrease in duration of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>. </p>
<p>In studies of recurrent <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> and of <span class="product-label-link" type="condition" conceptid="140027" conceptname="Herpetic gingivostomatitis">herpes labialis</span> in non-immunocompromised patients, there was no evidence of clinical benefit; there was some decrease in duration of viral shedding.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_17ac43bb-d96b-4a94-ab5c-1defc438460b"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Acyclovir ointment 5% is indicated in the management of initial <span class="product-label-link" type="condition" conceptid="200319" conceptname="Herpetic infection of penis">genital herpes</span> and in limited non-life threatening mucocutaneous Herpes simplex virus <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in immunocompromised patients.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_21808a47-1a60-4601-bcd5-8e357ccc8633"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Acyclovir ointment 5% is contraindicated in patients who develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the components of the formulation.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_b892d72d-b638-4135-ac8f-b437b7fc0947"></a><a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Acyclovir ointment 5% is intended for cutaneous use only and should not be used in the eye.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_5ebe2a31-200c-42a4-ab81-788ea727ae45"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_cb709263-4f35-4938-ab44-90f9f45d5bbd"></a><a name="section-8.1"></a><p></p>
<h2>General</h2>
<p class="First">The recommended dosage, frequency of applications and length of treatment should not be exceeded (see <a href="#i4i_dosage_admin_id_ca06b5c3-909a-45db-8863-4c21bdcbb768">DOSAGE AND ADMINISTRATION</a>). There are no data to support the use of acyclovir ointment 5% to prevent transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to other persons or prevent recurrent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> when applied in the absence of signs and symptoms. Acyclovir ointment 5% should not be used for the prevention of recurrent HSV <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. Although clinically significant viral resistance associated with the use of acyclovir ointment 5% has not been observed, this possibility exists.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_interactions_id_39c4adb6-9733-4f03-a09d-a97b807d343a"></a><a name="section-8.2"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Clinical experience has identified no interactions resulting from topical or systemic administration of other drugs concomitantly with acyclovir ointment 5%.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_id_904f8027-6aae-443d-8094-993c1a5d3ace"></a><a name="section-8.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Systemic exposure following topical administration of acyclovir is minimal. Dermal carcinogenicity studies were not conducted. Results from the studies of carcinogenesis, mutagenesis and fertility are not included in the full prescribing information for acyclovir ointment 5% due to the minimal exposures of acyclovir that result from dermal application. Information on these studies is available in the full prescribing information for acyclovir capsules, tablets and suspension and acyclovir for injection.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_id_d3f38ac9-db54-43cd-bdbe-1f12d8149353"></a><a name="section-8.4"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_id_edebc098-1923-495c-a85a-9fb8b104d71c"></a><a name="section-8.4.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_b2fb9ef7-d186-4756-8299-d66ff8353567"></a><a name="section-8.4.1.1"></a><p></p>
<h4><span class="Bold">Pregnancy Category B</span></h4>
<p class="First">Acyclovir was not teratogenic in the mouse, rabbit or rat at exposures greatly in excess of human exposure. There are no adequate and well controlled studies of systemic acyclovir in pregnant women. A prospective epidemiologic registry of acyclovir use during pregnancy was established in 1984 and completed in April 1999. There were 749 pregnancies followed in women exposed to systemic acyclovir during the first trimester of pregnancy resulting in 756 outcomes. The occurrence rate of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> approximates that found in the general population. However, the small size of the registry is insufficient to evaluate the risk for less common defects or to permit reliable or definitive conclusions regarding the safety of acyclovir in pregnant women and their developing fetuses. Systemic acyclovir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_id_aa82ac45-7a9d-4448-8f0b-976903e05b49"></a><a name="section-8.5"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether topically applied acyclovir is excreted in breast milk. Systemic exposure following topical administration is minimal. After oral administration of acyclovir, acyclovir concentrations have been documented in breast milk in two women and ranged from 0.6 to 4.1 times the corresponding plasma levels. These concentrations would potentially expose the nursing infant to a dose of acyclovir up to 0.3 mg/kg per day. Nursing mothers who have active herpetic lesions near or on the breast should avoid nursing.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="i4i_geriatric_use_id_84260c94-00a6-4e3f-9dd9-eeab8be551df"></a><a name="section-8.6"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of acyclovir ointment did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. Systemic absorption of acyclovir after topical administration is minimal (see <a href="#i4i_clinical_pharmacology_id_9f24053a-dadb-4cf8-84e4-4dfec53bf289">CLINICAL PHARMACOLOGY</a>).</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_ab0aebcc-cc61-42f8-a63e-1abfc3170908"></a><a name="section-8.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_6f8bdfa6-c72f-464e-9e27-5615ffaca59e"></a><a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">In the controlled clinical trials, mild <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (including transient burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span>) was reported by about 30% of patients in both the active and placebo arms; treatment was discontinued in two of these patients. Local <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> occurred in 4% of these patients. In all studies, there was no significant difference between the drug and placebo group in the rate or type of reported adverse reactions nor were there any differences in abnormal clinical laboratory findings.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0003740c-9760-46e7-9d76-ca711abc8426"></a><a name="section-9.1"></a><p></p>
<h2>Observed During Clinical Practice</h2>
<p class="First">Based on clinical practice experience in patients treated with acyclovir ointment in the U.S., spontaneously reported adverse events are uncommon. Data are insufficient to support an estimate of their incidence or to establish causation. These events may also occur as part of the underlying disease process. Voluntary reports of adverse events that have been received since market introduction include:</p>
<p><span class="Bold"><span class="Italics">General: </span></span><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span> and/or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at the application site.</p>
<p><span class="Bold"><span class="Italics">Skin: </span></span><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_id_21a95875-952f-4f5c-84a4-046815fb6f91"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Overdosage by topical application of acyclovir ointment 5% is unlikely because of limited transcutaneous absorption (see <a href="#i4i_clinical_pharmacology_id_9f24053a-dadb-4cf8-84e4-4dfec53bf289">CLINICAL PHARMACOLOGY</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_ca06b5c3-909a-45db-8863-4c21bdcbb768"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Apply sufficient quantity to adequately cover all lesions every 3 hours, 6 times per day for 7 days. The dose size per application will vary depending upon the total lesion area but should approximate a one-half inch ribbon of ointment per 4 square inches of surface area. A finger cot or rubber glove should be used when applying acyclovir ointment to prevent autoinoculation of other body sites and transmission of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> to other persons. <span class="Bold">Therapy should be initiated as early as possible following onset of signs and symptoms.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_c6122f69-4d4a-4973-9f98-dd221c57d9df"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Each gram ofAcyclovir Ointment USP, 5% contains acyclovir USP, 50 mg in a polyethylene glycol base. Acyclovir Ointment USP, 5% is an opaque white to off-white ointment available as follows: </p>
<p>0378-8700-06<br>carton of one 15 g tube</p>
<p>0378-8700-49<br>carton of one 30 g tube</p>
<p>Keep out of the reach of children. </p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] </span></p>
<p><span class="Bold">Store in a dry place.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p>REVISED FEBRYARY 2013<br>ACYCO:R2<br>1193.2</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_2a8f6de2-4361-407a-98f7-6d48ac089bb3"></a><a name="section-13"></a><p></p>
<h1>      </h1>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL </span></p>
<p><span class="Bold">NDC 0378-8700-06     Rx only</span></p>
<p><span class="Bold">Acyclovir     5%</span><br><span class="Bold">Ointment, USP </span><br><span class="Bold">15 g</span></p>
<p>Each gram contains acyclovir, USP 50 mg in a polyethylene glycol base.</p>
<p><span class="Bold">Usual Dosage:</span> Apply 6 times a day (every 3 hours) for 7 days.<br>See prescribing information for dosage information.</p>
<p><span class="Bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</span></p>
<p><span class="Bold">Store in a dry place.</span></p>
<p>Manufactured for:<br><span class="Bold">Mylan Pharmaceuticals Inc.</span><br>Morgantown, WV 26505 U.S.A.</p>
<p><span class="Bold">Mylan.com</span></p>
<p>1215.2</p>
<p>M8700:06:1C:R2</p>
<div class="Figure">
<a name="id107965858"></a><img alt="Acyclovir Ointment 5% Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=ce3d5e8b-9401-40be-8ce7-4ea42113f4ab&amp;name=ab3c9c7e-1bda-4579-9b90-2133c99c95a8-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>ACYCLOVIR 		
					</strong><br><span class="contentTableReg">acyclovir ointment</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0378-8700</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>ACYCLOVIR</strong> (ACYCLOVIR) </td>
<td class="formItem">ACYCLOVIR</td>
<td class="formItem">50 mg  in 1 g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (opaque white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">    </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0378-8700-06</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0378-8700-49</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">30 g in 1 TUBE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202459</td>
<td class="formItem">04/03/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Mylan Pharmaceuticals Inc.
							(059295980)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>ab3c9c7e-1bda-4579-9b90-2133c99c95a8</div>
<div>Set id: ce3d5e8b-9401-40be-8ce7-4ea42113f4ab</div>
<div>Version: 5</div>
<div>Effective Time: 20130228</div>
</div>
</div> <div class="DistributorName">Mylan Pharmaceuticals Inc.</div></p>
</body></html>
